Summary
Boston Scientific Corporation (BSX) filed an 8-K report on November 6, 2019, detailing significant financing activities. The company announced the early results and pricing of a cash tender offer for up to $1.0 billion of its outstanding senior notes across several maturity dates. This initiative is aimed at managing its existing debt structure.
Key Highlights
- 1Announced early results and pricing for a cash tender offer to repurchase up to $1.0 billion of outstanding senior notes.
- 2The tender offer covers notes due in 2023, 2028, 2025, and 2022.
- 3Priced a public offering of €900,000,000 (approximately $1.0 billion) in 0.625% notes due 2027.
- 4The offering is expected to close on November 12, 2019.
- 5Proceeds from the new note offering are intended to fund the tender offer.
- 6Any remaining proceeds from the offering will be used for repayment of other indebtedness and general corporate purposes.
- 7The tender offer's consummation is subject to a financing condition.
Frequently Asked Questions
The primary purpose is to proactively manage Boston Scientific's debt structure by repurchasing existing notes through a tender offer and funding it with proceeds from a new debt issuance.
The company is conducting a cash tender offer for up to $1.0 billion in aggregate principal amount of its outstanding senior notes.
Boston Scientific priced a public offering of €900,000,000 (approximately $1.0 billion) in new notes due 2027, and intends to use the net proceeds from this offering to fund the tender offer.
The public offering of new notes is expected to close on November 12, 2019. The tender offer's consummation is subject to a financing condition.